Treatment with liraglutide as adjunct to insulin in type 1 diabetes; effects on counter regulatory response to hypoglycaemia: a randomised, double blind, crossover trial

被引：0
|
作者：
Pieber, T. R. [1 ]
Deller, S. [1 ]
Brunner, M. [1 ]
Jensen, L. [2 ]
Christiansen, E. [3 ]
Kiyomi, F. [4 ]
Heller, S. R. [5 ]
机构：
[1] Med Univ Graz, Graz, Austria
[2] Novo Nordisk AS, Pharmacol Diabet, Soborg, Denmark
[3] Novo Nordisk AS, GLP & Obes 1, Soborg, Denmark
[4] Novo Nordisk Pharma Ltd, Tokyo, Japan
[5] Univ Sheffield, Sheffield S10 2TN, S Yorkshire, England
来源：
DIABETOLOGIA | 2013年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1007
引用
收藏
页码：S404 / S405
页数：2
相关论文
共 50 条
  • [1] Effects of Liraglutide as Adjunct to Insulin on Counter-Regulatory Hormone Responses to Hypoglycemia in Type 1 Diabetes: A Randomized, Double-Blind, Crossover Trial
    Pieber, Thomas
    Deller, Sigrid
    Brunner, Martina
    Jensen, Lene
    Christiansen, Erik
    Kiyomi, Fumiaki
    Heller, Simon
    DIABETES, 2013, 62 : A258 - A258
  • [2] Positive effects of liraglutide as adjunct to insulin in type 1 diabetes: glycaemic control and safety in a randomised, double blind, placebo controlled crossover trial
    Heller, S. R.
    Korsatko, S.
    Gurban, J.
    Jensen, L.
    Christiansen, E.
    Kiyomi, F.
    Pieber, T. R.
    DIABETOLOGIA, 2013, 56 : S7 - S8
  • [3] Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial
    Pieber, T. R.
    Deller, S.
    Korsatko, S.
    Jensen, L.
    Christiansen, E.
    Madsen, J.
    Heller, S. R.
    DIABETES OBESITY & METABOLISM, 2015, 17 (08): : 742 - 750
  • [4] Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes
    Heller, SR
    Colagiuri, S
    Vaaler, S
    Wolffenbuttel, BHR
    Koelendorf, K
    Friberg, HH
    Windfeld, K
    Lindholm, A
    DIABETIC MEDICINE, 2004, 21 (07) : 769 - 775
  • [5] Liraglutide as Adjunct to Insulin in Type 1 Diabetes: Effects on Glycemic Control and Safety in a Randomized, Double-Blind, Crossover Trial
    Heller, Simon R.
    Korsatko, Stefan
    Gurban, Jamala
    Jensen, Lene
    Christiansen, Erik
    Kiyomi, Fumiaki
    Pieber, Thomas R.
    DIABETES, 2013, 62 : A258 - A259
  • [6] Efficacy and safety of liraglutide added to capped insulin treatment in type 1 diabetes, the ADJUNCT TWO™ randomised trial
    Hirsch, I. B.
    Ahren, B.
    Pieber, T.
    Mathieu, C.
    Gomez-Peralta, F.
    Hansen, T.
    Philotheou, A.
    Christiansen, E.
    Jensen, T. J.
    Birch, S.
    Buse, J.
    DIABETOLOGIA, 2016, 59 : S357 - S357
  • [7] Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study
    Gerd Koehler
    Simon Heller
    Stefan Korsatko
    Carsten Roepstorff
    Søren Rasmussen
    Hanne Haahr
    Thomas R. Pieber
    Diabetologia, 2014, 57 : 40 - 49
  • [8] Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study
    Koehler, Gerd
    Heller, Simon
    Korsatko, Stefan
    Roepstorff, Carsten
    Rasmussen, Soren
    Haahr, Hanne
    Pieber, Thomas R.
    DIABETOLOGIA, 2014, 57 (01) : 40 - 49
  • [9] Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes, the ADJUNCT ONE™ treat-to-target randomised trial
    Zinman, B.
    Bode, B.
    Hemmingson, J. U.
    Woo, V.
    Colman, P.
    Christiansen, E.
    Linder, M.
    Mathieu, C.
    DIABETOLOGIA, 2016, 59 : S1 - S2
  • [10] SWITCH 1: reduced risk of hypoglycaemia with insulin degludec vs insulin glargine U100 in patients with type 1 diabetes: a randomised, double-blind, crossover trial
    Lane, W.
    Bailey, T. S.
    Gerety, G.
    Gumprecht, J.
    Philis-Tsimikas, A.
    Hansen, C. T.
    Nielsen, T. S. S.
    Warren, M. L.
    DIABETOLOGIA, 2016, 59 : S42 - S43
12345